Trial Profile
An evaluation of the effectiveness of Pulmicort Respules (budesonide inhalation suspension) versus Singulair (montelukast sodium) in children 2-8 years old with asthma requiring controller therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2008
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 12 Apr 2008 New trial record.